The United States Prostate Cancer Biomarkers Market is projected to grow from $1.48 billion in 2024 to $3.54 billion by 2033, ...

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in ...

NICE recommends Bayer’s Nubeqa® (darolutamide) plus androgen deprivation therapy as a treatment option for patients with hormone-sensitive metastatic prostate cancer Nubeqa® (darolutamide) plus ...

Scientists uncover a molecular weakness that could transform prostate cancer therapy. An international team of researchers has identified a new weakness in prostate cancer cells that could enhance ...

GSK shares lifted on Monday after the pharmaceutical giant signed a £268m deal with French biotech Syndivia for a potential treatment for prostate cancer.

GSK has boosted its pipeline of antibody-drug conjugates for cancer, licensing a prostate cancer candidate from Syndivia in a ...

GSK is set to acquire the exclusive rights for Syndivia’s preclinical antibody-drug conjugate (ADC), which is currently in ...

These preclinical data underscore the potential of ORIC-944 to overcome resistance not only in prostate cancer but in other solid tumors and highlight that the therapeutic potential of PRC2 inhibition ...

Lung cancer is the second most common cancer in both men and women in the United States and the leading cause of cancer-related deaths - more than colon, breast and prostate cancers combined. Many ...

WINTERSET, Iowa - Mackenzie Dryden’s happiest childhood memories are of running barefoot through the sunlit corn fields of her hometown. But when she was diagnosed with cancer 2½ years ago at 18 years ...

A major European clinical research event in oncology gives a boost to antibody–drug conjugates, treatments that work like a Trojan horse, delivering chemotherapy to the interior of malignant cells ...

NetworkNewsWire Editorial Coverage NEW YORK, Oct. 27, 2025 /PRNewswire/ -- The global oncology market is rapidly shifting ...